3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||480.447 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Pindobind is a compound developed by researchers associated with Stanford University, identified as a central nervous system depressant, which generated a response in animals reducing offensive actions such as chasing, while also notably reducing tendencies of the test animal to evade when stimulated to do so. It acts as an irreversible beta blocker and irreversible 5-HT1A receptor antagonist.
- Peroutka, Stephen J.; Pitha, Josef (Jul 20, 1993), Method for relieving anxiety using 5-hydroxytryptamine-1a-receptor-binding compounds, retrieved 2016-06-04
- Bell, R; Hobson, H (1993). "Effects of pindobind 5-hydroxytryptamine1A (5-HT1A), a novel and potent 5-HT1A antagonist, on social and agonistic behaviour in male albino mice". Pharmacology Biochemistry and Behavior. 46 (1): 67–72. doi:10.1016/0091-3057(93)90318-N. PMID 8255924.
|α1- + β-selective|